Innovation in science and stem cell technology

Changing the paradigm for stem cell therapy

 
Our platform
StemMedical_Logo_Icon_white
S_DSC0808_20171117141501_edit

We improve the quality of life of

By discovering and developing innovative biological MSC stem cells therapies and make them accessible to patients throughout the world.

By keeping our patients’ and customers’ safety and well-being at the core of everything we do.

By partnering with leading hospitals, healthcare professionals and academia.

Our business in numbers

20B

ASCs from 100 ml of adipose tissue over 2 weeks 3D cell culturing
80%

Patent coverage of global market until 2034
80%

More volume (fat retention) compared to conventional fat grafting published in The Lancet
67

Real World Patients treated
STEMFORM_473_Capture
Science

Our platform

Our core science is focused on producing and expanding very high quantities of potent autologous MSCs. Despite the many opportunities in cell therapy, the focus of StemMedical is clear and divided into two main strategic segments.
Read More
Therapeutics

Stemtreat

focuses on using the technology for hard-to-treat inflammatory conditions with initial focus on musculoskeletal disorders.
Read More
Closeup tendon knee joint problems on woman leg indicated with red spot isolated on gray background. Joint inflammation concept.
STEMFORM11932-1100x733
Plastic Surgery

Stemform

covers the cosmetic application of the technology. Stemform cultured stem cell fat transfer treatment offers women a natural and effective breast augmentation as an alternative to artificial implants. 

 
Read More

StemMedical is a versatile mesenchymal stem cell therapy platform with broad applicability

Latest insights

STEMFORM12856 copy
Stemform

Startup hyrede ham efter 18 år i Novo Nordisk: Nu vil han skabe raketvækst på fedt til bryster.

Stem Medical vil erstatte brystimplantater med en stamcellebaseret løsning – nye investorer skal sikre europæisk udrulning.
Read article
STEMFORM_407_Capture
Cell Therapy

LSX World Congress 2023

Leading investors discuss the global investment landscape and shifts in public and private finance, as well as what they expect 2023 and onwards to hold.
Read article
STEMFORM_473_Capture
Investor

Stamcelleselskab har sikret sig halvdelen af ønsket kapital

Stamcellefirmaet Stemmedical indledte i sommeren 2022 en pengerunde, der skulle sikre selskabet i alt 15 mio. euro, svarende til næsten 112 mio. kr., og nu er halvdelen af pengene i hus, oplyser Stemmedical til Børsen.
Read article
MORE INSIGHTS

StemMedical®

Empower Cells to Empower People